Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

Parejo-Alonso, Beatriz; Royo-García, Alba; Espiau-Romera, Pilar; Courtois, Sarah; Curiel-García, Álvaro; Zagorac, Sladjana; Villaoslada, Isabel; Olive, Kenneth P.; Heeschen, Christopher; Sancho, Patricia

doi:10.1016/j.biopha.2022.114162

Cited by 5 publications

(2 citation statements)

References 59 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RNAi-mediated abrogation of MDK restored the chemosensitivity of the resistant cells towards gemcitabine. Alonso et al blocked the ALK signaling pathway, which is one of the receptors for MDK binding, thereby inhibiting proliferation, self-renewal, tumorigenicity, and chemoresistance of the PDAC cells [26].…”

Section: Pancreatic Ductal Adenocarcinoma (Pdac)mentioning

confidence: 99%

“…Midkine is found to play a pivotal role in multi-drug resistance via different mechanisms such as inducing the overexpression of pro-proliferative molecules, inducing epithelial-mesenchymal transition (EMT), or others, such as increasing drug efflux pumps [22,24,25]. Inhibiting or downregulating MDK expression by using RNAi or siRNA shows drug sensitivity reverting to the resistant cells along with the enhancement in the efficacy of the chemotherapeutic agent [26,27]. However, not much is known about the regulation of MDK's expression and function.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting

Saikia

Cheung

Singh

et al. 2023

IJMS

View full text Add to dashboard Cite

Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.

show abstract

Section: Pancreatic Ductal Adenocarcinoma (Pdac)mentioning

confidence: 99%